Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02036307 · ClinicalTrials.gov registry record · Phase 2
Supplementation With Omega-3: Mechanism of Action
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT02036307: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT02036307 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02036307, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a trial of two marketed fish oil supplements, one with a high EPA:DHA ratio and the other with a high DHA:EPA ratio, to examine differential effects on platelet function, blood pressure, and fasting triglyceride levels.
Interventions
- DIETARY_SUPPLEMENT DHA-enriched
- DIETARY_SUPPLEMENT EPA-enriched
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02036307
The ClinicalTrials.gov registry entry for NCT02036307 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DHA-enriched is the first listed.
NCT02036307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02036307 about?
NCT02036307 is a clinical study titled "Supplementation With Omega-3: Mechanism of Action". This is a trial of two marketed fish oil supplements, one with a high EPA:DHA ratio and the other with a high DHA:EPA ratio, to examine differential effects on platelet function, blood pressure, and fasting triglyceride levels.
What is the current status of trial NCT02036307?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2013-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02036307?
The interventions under investigation include: DHA-enriched (DIETARY_SUPPLEMENT), EPA-enriched (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02036307?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.